Biogradient

Company Overview

Snapshot

Founded in May 2019 by Ron Gutterman and Gal Tichon, Biogradient operated with 11–50 employees. The company ceased to operate in March 2025.

Business overview

Biogradient developed a digital sensor-based system leveraging physiological algorithms and artificial intelligence to maximize personalized physiological capabilities. Its advanced AI-driven algorithms were integrated into solutions for medicine, sports, and insurance, focusing on goal-oriented, supervised exercise prescriptions adaptable to patient schedules. The company operated within the Health Tech & Life Sciences sector, specifically targeting Digital Healthcare, Patient Remote Monitoring, and Sports Tech markets.

Strategic signal

Biogradient ceased operations in March 2025. This event signals a complete cessation of business activities, indicating that the company is no longer pursuing its mission of developing digital sensor-based systems for personalized physiological capabilities. For investors and innovation teams, this marks a definitive conclusion to the company's trajectory in the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Biogradient's primary focus?

Biogradient focuses on developing physiological algorithms and artificial intelligence for a digital sensor-based system aimed at maximizing personalized physiological capabilities.

When was Biogradient founded?

Biogradient was founded in May 2019.

Who are the founders of Biogradient?

Ron Gutterman and Gal Tichon are the co-founders of Biogradient.

What markets did Biogradient serve?

Biogradient's advanced algorithms were integrated into solutions for the medicine, sports, and insurance fields.

What is the current status of Biogradient?

Biogradient ceased to operate in March 2025.